11/20/2018

Recent Oncology Related Drug News

New Medicare Part D Opioid Prescribing Policies for 2019—What You Need to Know

(ASCO in Action) Nov 16, 2018 - Effective January 1, 2019, Medicare is instituting new opioid prescribing policies that will impact Medicare Part D beneficiaries with a prescription drug benefit and their prescribers. READ ARTICLE

IMFINZI^® (durvalumab) injection has been assigned a unique HCPCS code by CMS

IMFINZI^® (durvalumab) injection has been assigned a unique HCPCS code by CMS.  Effective for dates of services on or after January 1, 2019, the following code can be used to identify IMFINZI^® (durvalumab) :

AstraZeneca Access 360™ can help with questions you may have about coding and reimbursement. For additional assistance, please contact your Reimbursement Counselor at 1-833-360-4357, Monday through Friday from 8 AM to 8 PM Eastern Time, or visit www.MyAccess360.com.

UnitedHealthcare Names 3 Biosimilars Preferred Treatments in 2019 MA Plans

When CMS announced in August 2018 its policy change to allow Medicare Advantage (MA) plans to utilize step therapy as a way to negotiate drug prices, UnitedHealthcare, the nation’s largest MA carrier, publicly celebrated the decision. This week, the insurer rolled out some of the changes it will be implementing in its MA plans as of January 1, 2019.

Read the full article on The Center for Biosimilars here.